Cenduit Launches New Professional Services Division
The Professional Services Division, provides hands-on experience for managing and enhancing Interactive Response Technology (IRT) systems.
Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, announced its new Professional Services Division, to provide hands-on experience for managing and enhancing Interactive Response Technology (IRT) systems.
Features of the new division include:
- Support with complex third-party system integrations and customizations
- Consulting for complex studies that require focused support
- Protocol-specific consulting (for example, needing an IVR set up where the patient will call in and report adverse events)
- Business analytics and reporting such as forecasting dashboard, enabling with effective decision support system for optimization.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
